Investigational Drug Details
| Drug ID: | D371 |
| Drug Name: | Tocotrienol |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | DB12647 |
| DrugBank Description: | Tocotrienol has been investigated for the treatment of Cholesterol Lowering. |
| PubChem ID: | 9929901 |
| CasNo: | 6829-55-6 |
| Repositioning for NAFLD: | No |
| SMILES: | C(CC=C(CCC=C(CCC=C(C)C)C)C)C1(C)Oc2c(CC1)cc(cc2)O |
| Structure: |
|
| InChiKey: | GJJVAFUKOBZPCB-UHFFFAOYSA-N |
| Molecular Weight: | 382.588 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | HMG-CoA inhibitor |
| Therapeutic Category: | Enhance lipid metabolism |
| Clinical Trial Progress: | Phase 2 on-going (NCT04704063) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0088 | NCT04704063 | Phase 2 | Recruiting | No Results Available | January 1, 2021 | October 6, 2021 | Details |
| L0608 | NCT02581085 | Phase 2 | Recruiting | No Results Available | 26/06/2015 | 22 February 2021 | Details |
| L0725 | SLCTR/2019/038 | Phase 2 | Not Recruiting | No Results Available | 16/10/2019 | 7 February 2022 | Details |
| L0863 | SLCTR/2015/023 | Phase 2 | Recruiting | No Results Available | 03/10/2015 | 7 February 2022 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00050 | 35243111 | Transl Gastroenterol Hepatol | Palm tocotrienol rich fraction with palm kernel oil supplementation prevents development of liver steatosis in high fat diet ICR mice. | Details |
| A01552 | 34697380 | Sci Rep | Untargeted serum metabolites profiling in high-fat diet mice supplemented with enhanced palm tocotrienol-rich fraction using UHPLC-MS. | Details |
| A02620 | 34307250 | Front Pediatr | Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents. | Details |
| A03630 | 33924725 | Nutrients | The Combination of Berberine, Tocotrienols and Coffee Extracts Improves Metabolic Profile and Liver Steatosis by the Modulation of Gut Microbiota and Hepatic miR-122 and miR-34a Expression in Mice. | Details |
| A06255 | 32951743 | Complement Ther Med | Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial. | Details |
| A13009 | 30183139 | Mol Nutr Food Res | Gamma-Tocotrienol Attenuates the Hepatic Inflammation and Fibrosis by Suppressing Endoplasmic Reticulum Stress in Mice. | Details |
| A13800 | 29749323 | Turk J Gastroenterol | Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease. | Details |
| A15588 | 28825992 | J Nutr Biochem | Effects of delta-tocotrienol on obesity-related adipocyte hypertrophy, inflammation and hepatic steatosis in high-fat-fed mice. | Details |
| A15777 | 28714405 | Curr Pharm Des | Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter. | Details |
| A22671 | 24373555 | Nutr J | Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial. | Details |
| A32658 | 27816611 | Free Radic Biol Med | Vitamin E: Emerging aspects and new directions. | Details |
| A34238 | 23995653 | Biol Pharm Bull | Peroxisome proliferator-activated receptor γ (PPARγ)-independent specific cytotoxicity against immature adipocytes induced by PPARγ antagonist T0070907. | Details |
| A34410 | 23526264 | J Clin Biochem Nutr | Effects of tocotrienol on tumor necrosis factor-α/d-galactosamine-induced steatohepatitis in rats. | Details |
| A43589 | 31341440 | Integr Med (Encinitas) | Barrie Tan, PhD: Using Tocotrienols to Address Lifestyle and Metabolic Disease. | Details |
| A50745 | 35280867 | Front Med (Lausanne) | Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | Details |
| A51349 | 35400820 | J Clin Biochem Nutr | Effect of tocotrienol on the primary progression of nonalcoholic steatohepatitis in a mouse model. | Details |